Mepride-VM 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, mitigating postprandial hyperglycemia. The synergistic action of these three agents addresses multiple pathophysiological defects of type 2 diabetes, offering comprehensive glycemic management. Mepride-VM 2 Tablet SR is indicated for patients inadequately controlled by diet and exercise alone or those requiring combination therapy to achieve target blood glucose levels. It is essential to monitor renal function prior to and during therapy due to Metformin’s renal clearance. The sustained-release formulation ensures steady plasma drug concentrations, enhancing patient compliance and minimizing gastrointestinal side effects. This medication should be used under medical supervision, with regular monitoring of blood glucose and HbA1c levels to adjust dosage and prevent hypoglycemia or lactic acidosis.